Adults

A single 0.5 mL dose administered intramuscularly (IM) or subcutaneously (SC). Re-vaccination may be considered after 5 years for certain high-risk individuals.

Elderly

A single 0.5 mL dose administered intramuscularly (IM) or subcutaneously (SC). Generally, one dose is sufficient, but re-vaccination may be considered based on individual risk factors and guidelines.

Renal_impairment

No specific dose adjustment is needed for individuals with renal impairment.

Onset

Immune response (antibody production) typically begins within 2-3 weeks post-vaccination.

Excretion

Not applicable to the vaccine antigen; antibodies are cleared over time through normal physiological processes.

Half life

Not applicable to the vaccine antigen itself; refers to the persistence of vaccine-induced antibodies, which varies.

Absorption

As a vaccine, traditional absorption kinetics do not apply. The antigens are processed by antigen-presenting cells to elicit an immune response.

Metabolism

Antigens are processed and presented by immune cells; they are not metabolized in the same way as small molecule drugs.

Other vaccines

Pneumovax 23 can be administered concurrently with other vaccines (e.g., influenza vaccine), but separate injection sites and different syringes should be used. Consult guidelines for specific co-administration recommendations.

Immunosuppressive therapy

Immunosuppressive treatments (e.g., corticosteroids, chemotherapy) may reduce the immune response to the vaccine, potentially leading to lower antibody levels and reduced protection.